Insider Purchases: Inside the Buy
Tag: Funanc1al for Investors
It’s Not Just Team Work: Atlassian Insider Invests Too
Atlassian (TEAM) isn’t just about team work—it’s insider work too. With new insider buys, strong institutional backing, and double-digit revenue growth, is TEAM ready to rally, or will competition and valuation risks keep it swiping left?
Eastman Chemical (EMN): Insider Chemistry at Work
Insiders from CEO to CFO are scooping up Eastman Chemical shares. With institutions owning 92% of the float and dividends flowing, is this a value play worth a reaction? 🧪📈
Western Union (WU): Cash Transfers, CEO Buys, and Maybe a Stock Rebound?
💸 Western Union’s CEO and CFO just wired big money into their own stock. Institutions already hold 95% of the float, but growth is flat, competition is fierce, and risks abound. Is this a bargain play — or a value trap in disguise?
Bakkt Holdings CEO Buys Shares; Are Profits Baked In?
Bakkt (BKKT) is back on the radar. With a new CEO buying $1.47M of stock and losses shrinking fast, is this crypto play baked to perfection—or half-baked hype?
Can Olin Cock Its Stock? Insiders Say Yes (Lock, Load, and Maybe Profit)
Olin ($OLN) insiders are loading up on shares while institutions already own 94% of the float. Profits are weak, ammo is hot, and bleach is… bleach. Can this 132-year-old company cock its stock for a rebound?
Is Boeing Ready to Fly?
Boeing’s new director — ex-Vanguard CEO Tim Buckley — just bought nearly $500K of stock. With a $619B backlog and cash flow stabilizing, is this aerospace giant finally ready for liftoff… or more turbulence?
COO Goes Shopping: Is Molina Healthcare (MOH) a Healthy Buy or Just a Check-Up?
When the COO of Molina Healthcare spends $1.56M on stock, investors notice. With Wall Street titans on board and shares at major support, is this a healthy buy — or a risky patient?
Figma (FIG): Directors Buy In — Should You Collaborate?
🎨 Figma stock exploded out of the IPO gate, hitting highs nearly 5x insider purchase prices. With no profits, big Bitcoin bets, and stiff competition, is this design darling still worth the hype? Let’s sketch it out—icons, jokes, and all.
MSCI Keeps Winning — and the CEO Keeps Buying In
MSCI delivers world-class data tools for investors—and its CEO just bought in big. With soaring revenue, recurring subscriptions, and loyal institutions, is this still a buy? Or has the stock outpaced its fundamentals?
Does Align Technology’s Recovery Plan Have Teeth? The CEO Thinks So.
Align Technology insiders are smiling—because they’re buying. With a CEO purchase nearing $1M and Wall Street holding more shares than exist, ALGN may be regaining its shine. But should you sink your teeth into it now?